Cara taps Korean firm as first licensee for its lead analgesic
This article was originally published in Scrip
Executive Summary
The US venture Cara Therapeutics has struck the first licensing deal for its lead product candidate CR845, allying with Chong Kun Dang Pharmaceutical (CKD) for the development and marketing of the analgesic in South Korea.
You may also be interested in...
Cara Ready To Move Into Pivotal Studies In ESRD Pruritus
With a successful end-of-Phase II meeting with FDA concluded, Cara moves closer to bringing the first drug to market for pruritus in ESRD patients on dialysis.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.